A szomatosztatinreceptor-expresszió változásá nak vizsgálata recidiváló medulloblastomában

Translated title of the contribution: Examination of somatostatin receptor expression in recurrent childhood medulloblastomas

Éva Kaszper, Z. Hanzély, B. Szende, Gabriella Dabasi, M. Garami, D. Schuler, P. Hauser

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Medulloblastoma is the most common malignant pediatric central nervous system tumor. Despite the adequate therapy the tumor often recurs. The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors. The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas. Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas. We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004. All primary and recurrent tumors have been operated at the National Institute of Neurosurgery. We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples. All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas. In our samples the percentage of SSTR-2- positive tumor cells was 30-90%. As a positive in vivo control Octreoscan images were available in two cases. In these cases the results of immunohistochemistry and Octreoscan imaging seemed to correlate. As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.

Original languageHungarian
Pages (from-to)351-355
Number of pages5
JournalMagyar Onkologia
Volume52
Issue number4
DOIs
Publication statusPublished - 2008

Fingerprint

Somatostatin Receptors
Medulloblastoma
Neoplasms
Immunohistochemistry
Pediatrics
somatostatin receptor 2
Central Nervous System Neoplasms
Octreotide
Neurosurgery
Somatostatin
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A szomatosztatinreceptor-expresszió változásá nak vizsgálata recidiváló medulloblastomában. / Kaszper, Éva; Hanzély, Z.; Szende, B.; Dabasi, Gabriella; Garami, M.; Schuler, D.; Hauser, P.

In: Magyar Onkologia, Vol. 52, No. 4, 2008, p. 351-355.

Research output: Contribution to journalArticle

@article{154798fe67294adebd63f4e29cd43108,
title = "A szomatosztatinreceptor-expresszi{\'o} v{\'a}ltoz{\'a}s{\'a} nak vizsg{\'a}lata recidiv{\'a}l{\'o} medulloblastom{\'a}ban",
abstract = "Medulloblastoma is the most common malignant pediatric central nervous system tumor. Despite the adequate therapy the tumor often recurs. The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors. The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas. Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas. We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004. All primary and recurrent tumors have been operated at the National Institute of Neurosurgery. We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples. All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas. In our samples the percentage of SSTR-2- positive tumor cells was 30-90{\%}. As a positive in vivo control Octreoscan images were available in two cases. In these cases the results of immunohistochemistry and Octreoscan imaging seemed to correlate. As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.",
keywords = "Immunohistochemistry, Medulloblastoma, Octreoscan, Pediatric brain tumor, Recurrent medulloblastoma, Somatostatin receptor, SSTR",
author = "{\'E}va Kaszper and Z. Hanz{\'e}ly and B. Szende and Gabriella Dabasi and M. Garami and D. Schuler and P. Hauser",
year = "2008",
doi = "10.1556/MOnkol.52.2008.4.3",
language = "Hungarian",
volume = "52",
pages = "351--355",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - A szomatosztatinreceptor-expresszió változásá nak vizsgálata recidiváló medulloblastomában

AU - Kaszper, Éva

AU - Hanzély, Z.

AU - Szende, B.

AU - Dabasi, Gabriella

AU - Garami, M.

AU - Schuler, D.

AU - Hauser, P.

PY - 2008

Y1 - 2008

N2 - Medulloblastoma is the most common malignant pediatric central nervous system tumor. Despite the adequate therapy the tumor often recurs. The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors. The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas. Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas. We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004. All primary and recurrent tumors have been operated at the National Institute of Neurosurgery. We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples. All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas. In our samples the percentage of SSTR-2- positive tumor cells was 30-90%. As a positive in vivo control Octreoscan images were available in two cases. In these cases the results of immunohistochemistry and Octreoscan imaging seemed to correlate. As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.

AB - Medulloblastoma is the most common malignant pediatric central nervous system tumor. Despite the adequate therapy the tumor often recurs. The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors. The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas. Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas. We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004. All primary and recurrent tumors have been operated at the National Institute of Neurosurgery. We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples. All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas. In our samples the percentage of SSTR-2- positive tumor cells was 30-90%. As a positive in vivo control Octreoscan images were available in two cases. In these cases the results of immunohistochemistry and Octreoscan imaging seemed to correlate. As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.

KW - Immunohistochemistry

KW - Medulloblastoma

KW - Octreoscan

KW - Pediatric brain tumor

KW - Recurrent medulloblastoma

KW - Somatostatin receptor

KW - SSTR

UR - http://www.scopus.com/inward/record.url?scp=59849099680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849099680&partnerID=8YFLogxK

U2 - 10.1556/MOnkol.52.2008.4.3

DO - 10.1556/MOnkol.52.2008.4.3

M3 - Article

VL - 52

SP - 351

EP - 355

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -